Company: Eli Lilly and Company
Job title: Senior Engineering Advisor, Process Design & Development
Martin D. Johnson works for Eli Lilly and Company in Small Molecule Design and Development. He received his dual doctorate in chemical engineering and environmental engineering from the University of Michigan in 2000, and his undergraduate in Chemical Engineering from Virginia Tech. Prior to joining Eli Lilly in 2005, he worked as a process research engineer at Union Carbide and The Dow Chemical Company in the Engineering Sciences and Market Development department, focusing on process development and separations. At Eli Lilly, Dr. Johnson leads a group of engineers who focus on design and development of continuous processes. Dr. Johnson’s group has used continuous reactions in the manufacture of active pharmaceutical ingredients for highly exothermic and hazardous reactions, high pressure reactions with hazardous gas reagent like hydrogenations, chemistries at extreme temperatures and pressures, and process separations including distillation, extraction, crystallization, and filtration. Eli Lilly has implemented his continuous processes for the production of active pharmaceutical ingredient in cGMP manufacturing both internally at the Lilly facility in Ireland and externally in multiple contract manufacturing organizations. Dr. Johnson was awarded the 2016 ACS Award for Affordable Green Chemistry for work with continuous aerobic oxidations, and the 2016 AIChE Award for Outstanding Contribution to QbD for Drug Substance for implementation of continuous processes.
Control for Achieving Desired Crystal Form in a Continuous Crystallization Process Scaled up to cGMP Manufacturing 3:00 pm
day: Stream 1 - Day 1 PM
Continuous Processing Potential Outside of Traditional Small Molecule & Monoclonal Antibody Applications 1:05 pm
• What technologies are available for cell, gene, and vaccine continuous manufacturing? • How close are these technologies to commercialization? – How easy are commercially available technologies able to be adapted to process needs? • What are the drivers for exploring CM for modalities outside of the traditional small molecules & monoclonal antibodies?Read more
day: Stream 2 - Day 2